Exhibit 10.3
Execution Copy
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.
University *of *Pennsylvania
Second Amendment to License Agreement
This Second Amendment to the License Agreement effective as of February 4, 2021 (this “Second Amendment”), is made by and between The Trustees of the University of Pennsylvania (“Penn”) and Kira Pharmaceuticals (“Licensee”) and amends the License Agreement between the parties, dated June 9, 2017, as amended by the First Amendment to License Agreement effective as of June 7, 2019 (the “License Agreement”; Penn agreement reference [***]). All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the License Agreement.
BACKGROUND
** **
WHEREAS, the License Agreement relates to certain intellectual property developed by Dr. Wenchao Song of Penn’s Perelman School of Medicine, which intellectual property is the subject of patents or patent applications and is related to antibody therapeutics against complement proteins C5, factor D and C5a (Penn docket references [***], [***] and [***]); and
WHEREAS, the Parties desire to amend the License Agreement pursuant to the terms and conditions of this Second Amendment.
NOW, THEREFORE, the parties hereby agree as follows:
| 1) | Section 2.4.1 of the License Agreement is hereby amended and restated as follows: |
“2.4.1 Penn grants to Licensee the right to grant sublicenses, in whole or in part, under the License (each, a “Sublicense”) subject to the terms and conditions of this Agreement and specifically this Section 2.4. The term Sublicense shall include any grant of rights under the License by a Sublicensee to any downstream third party, such downstream third party shall also be considered a Sublicensee for purposes of this Agreement. For clarity, the Licensee shave have the right to grant, in whole or in part, a Sublicense to any of its Affiliates and the Licensee shall have no obligation to provide any Sublicense Documents entered into with an Affiliate to Penn so long as such Affiliate agrees to be bound in writing by all of the terms and conditions of this Agreement.”
| 2) | This Second Amendment, together with the License Agreement, constitute the entire agreement between the parties. All other terms and provisions of the License Agreement, except as expressly amended by this Second Amendment, remain in full force and effect. |
| 3) | This Second Amendment may be executed in two or more counterparts, each of which shall be deemed an original and together shall be deemed one and the same instrument. |
[Signature page follows]
IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this Second Amendment to be executed by their duly authorized representatives.
| THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | ||
| By: | /s/ Benjamin Dibling, Ph.D. | |
| Name: | Benjamin Dibling, Ph.D. | |
| Title: | Deputy Managing Director, Penn Center for Innovation | |
| Date: | 2/22/2021 | |
| Kira Pharmaceuticals | ||
| By: | /s/ Frederick Beddingfield | |
| Name: | Dr. Frederick Beddingfield | |
| Title: | Chief Executive Officer | |
| Date: | 3/1/2021 |